May 16, 2022

HTA Quarterly | Summer 2022

By Amerisourcebergen

In this issue, our editors provide insights on the Institute for Clinical and Economic Review’s (ICER’s) recently published assessment of fair access criteria, a review of the lock system for orphan drugs in the Netherlands, and an analysis of the United Kingdom (UK) National Institute for Health and Care Excellence’s (NICE’s) new Health Technology Assessment (HTA) manuals.

The answer to the ultimate question of life, the universe, and everything? New NICE HTA manuals

The National Institute for Health and Care Excellence (NICE) recently published two new health technology assessment (HTA) manuals detailing updates and changes in the way it carries out the evaluation of health technologies. What does this mean for patients, the National Health Service (NHS), life science companies, and NICE itself?

Read article

HTA Quarterly | Summer 2022

Orphan drugs: trapped in the lock? A review of the lock system in the Netherlands

Whilst orphan diseases individually are rare, collectively they are not; population prevalence of rare diseases is put at 5% to 10%. Whilst developers look for high prices to cover their costs, can payers afford them? A review of the “lock” system in the Netherlands suggests maybe not.

Read article

HTA Quarterly | Summer 2022

Do fair prices lead to fair access? Supporting access with a comprehensive value proposition to bridge the gap

The Institute for Clinical and Economic Review (ICER) explores the “Grand Bargain” in a recently published assessment of fair access criteria among select US health plans. As predicted, plans may fall short in offering fair cost-sharing to patients. However, biopharma companies can encourage fair access by communicating a comprehensive product value proposition.

Read article

HTA by the numbers

71%

Elsevier Health’s “Clinician of the Future” global report found that 71% of doctors and 68% of nurses believe their jobs have changed considerably in the past decade, with many saying that their jobs have become more difficult. One in three clinicians are considering leaving their current role by 2024.

Read PharmaTimes Online: "Doctors and nurses produce roadmap to future-proof healthcare"

Heard on the street

“Exhausted and demoralised, they’ve emerged from two hellish years only to face longer and longer lists of sicker people.”

-Labour MP Dame Meg Hillier, chair of the Public Accounts Committee discussing the National Health Service staff in England facing a record 6.1 million patients waiting for non-urgent treatment

Read PharmaTimes Online: "Waiting game: a record 6.1 million NHS patients are currently waiting for non-urgent treatment"

HTA Quarterly | Summer 2022

The answer to the ultimate question of life, the universe, and everything? New NICE HTA manuals

Orphan drugs: trapped in the lock? A review of the lock system in the Netherlands

Do fair prices lead to fair access? Supporting access with a comprehensive value proposition to bridge the gap

HTA by the numbers

71%

Heard on the street

“Exhausted and demoralised, they’ve emerged from two hellish years only to face longer and longer lists of sicker people.”

Related Content

AmerisourceBergen は Cencora になりました

日本のヘルスケアロジスティクスの未来：国内航空輸送が変える、これからの患者ケア

AmerisourceBergenは、2023年よりCencora に変わります。